Haemonetics (HAE) to Release Earnings on Thursday

Haemonetics (NYSE:HAE) will likely be announcing its Q2 2026 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $1.12 per share and revenue of $311.6080 million for the quarter. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS.Parties may visit the the company’s upcoming Q2 2026 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.09. The firm had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The business’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period last year, the company earned $1.02 EPS. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Trading Up 0.5%

HAE stock opened at $50.28 on Tuesday. The business has a fifty day moving average of $51.17 and a 200-day moving average of $62.10. The company has a market cap of $2.42 billion, a P/E ratio of 15.38, a PEG ratio of 0.91 and a beta of 0.37. Haemonetics has a twelve month low of $47.31 and a twelve month high of $94.99. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on HAE shares. Raymond James Financial cut shares of Haemonetics from a “strong-buy” rating to an “outperform” rating and lowered their price target for the stock from $105.00 to $78.00 in a research report on Monday, August 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $68.00 price objective (down from $84.00) on shares of Haemonetics in a research note on Thursday, August 7th. Weiss Ratings cut shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Citigroup cut their price target on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, October 7th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $86.00 price objective on shares of Haemonetics in a research note on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.89.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after acquiring an additional 971 shares during the period. Caxton Associates LLP bought a new position in shares of Haemonetics during the 1st quarter valued at about $216,000. United Services Automobile Association acquired a new position in shares of Haemonetics in the 1st quarter valued at approximately $212,000. Empowered Funds LLC grew its position in shares of Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Haemonetics by 6.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after purchasing an additional 9,051 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.